Circulating Nampt and RBP4 levels in patients with carotid stenosis undergoing carotid endarterectomy (CEA)

Clinica Chimica Acta

Volumn 412, Issue 13-14, 2011, Pages 1195-1200

  Aust, Gabriela ^a   Uptaite Patapoviene, Migle ^a   Scholz, Markus ^a   Richter, Olaf ^a   Rohm, Silvio ^a   Blüher, Matthias ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Atherosclerosis; Carotid stenosis; Nampt; RBP4

Indexed keywords

NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RETINOL BINDING PROTEIN 4;

AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CELL COUNT; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOAM CELL; HUMAN; ISCHEMIA; LEUKOCYTE COUNT; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ADIPONECTIN; AGED; ASYMPTOMATIC DISEASES; ATHEROSCLEROSIS; CAROTID STENOSIS; ENDARTERECTOMY, CAROTID; FEMALE; HUMANS; ISCHEMIA; LEPTIN; MALE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; RETINOL-BINDING PROTEINS, PLASMA;

EID: 79955485123     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2011.03.008     Document Type: Article

References (50)

1. Caterson I.D., Hubbard V., Bray G.A., et al. Prevention Conference VII: obesity, a worldwide epidemic related to heart disease and stroke: Group III: worldwide comorbidities of obesity. Circulation 2004, 110:e476-e483.
2. Pischon T., Boeing H., Hoffmann K., et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008, 359:2105-2120.
3. Selwyn A.P. Weight reduction and cardiovascular and metabolic disease prevention: clinical trial update. Am J Cardiol 2007, 100:33-37.
4. Schneider H.J., Friedrich N., Klotsche J., et al. The predictive value of different measures of obesity for incident cardiovascular events and mortality. J Clin Endocrinol Metab 2010, 95:1777-1785.
5. Dandona P., Weinstock R., Thusu K., et al. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 1998, 83:2907-2910.
6. Ziccardi P., Nappo F., Giugliano G., et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002, 105:804-809.
7. Fantuzzi G., Mazzone T. Adipose tissue and atherosclerosis: exploring the connection. Arterioscler Thromb Vasc Biol 2007, 27:996-1003.
8. Berg A.H., Scherer P.E. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005, 96:939-949.
9. Rocha V.Z., Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009, 6:399-409.
10. Gupta A., Thomas P. Stroke prevention: missed opportunities?. Int J Clin Pract 2002, 56:338-341.
11. Wilson P.W., Bozeman S.R., Burton T.M., et al. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. Circulation 2008, 118:124-130.
12. Kadoglou N.P., Sailer N., Moumtzouoglou A., et al. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diab 2010, 118:75-80.
13. Sasaki M., Otani T., Kawakami M., Ishikawa S.E. Elevation of plasma retinol-binding protein 4 and reduction of plasma adiponectin in subjects with cerebral infarction. Metabolism 2010, 59:527-532.
14. Korner A., Garten A., Bluher M., et al. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007, 92:4783-4791.
15. Retnakaran R., Youn B.S., Liu Y., et al. Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin Endocrinol Oxf 2008, 69:885-893.
16. Milei J., Parodi J.C., Ferreira M., et al. Atherosclerotic plaque rupture and intraplaque hemorrhage do not correlate with symptoms in carotid artery stenosis. J Vasc Surg 2003, 38:1241-1247.
17. van Eijk M., Aust G., Brouwer M.S.M., et al. Expression of the EGF-TM7 family members CD97 and EMR2 in lipid-laden macrophages in atherosclerosis, multiple sclerosis and Gaucher disease. Immunol Lett 2010, 127:64-71.
18. Redgrave J.N., Lovett J.K., Gallagher P.J., Rothwell P.M. Histological assessment of 526 symptomatic carotid plaques in relation to the nature and timing of ischemic symptoms: the Oxford plaque study. Circulation 2006, 113:2320-2328.
19. Aust G., Richter O., Rohm S., et al. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis 2009, 204:262-266.
20. Bountouris I., Paraskevas K.I., Koutouzis M., et al. Serum leptin levels in patients undergoing carotid endarterectomy: a pilot study. Angiology 2009, 60:698-704.
21. Papas T.T., Maltezos C.K., Papanas N., et al. High-sensitivity CRP is correlated with neurologic symptoms and plaque instability in patients with severe stenosis of the carotid bifurcation. Vasc Endovasc Surg 2008, 42:249-255.
22. Alvarez G.B., Ruiz C., Chacon P., Sabin J.A., Matas M. High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque. J Vasc Surg 2003, 38:1018-1024.
23. Koutouzis M., Rallidis L.S., Peros G., et al. Serum interleukin-6 is elevated in symptomatic carotid bifurcation disease. Acta Neurol Scand 2009, 119:119-125.
24. Heider P., Pelisek J., Poppert H., Eckstein H.H. Evaluation of serum matrix metalloproteinases as biomarkers for detection of neurological symptoms in carotid artery disease. Vasc Endovasc Surg 2009, 43:551-560.
25. Montecucco F., Lenglet S., Gayet-Ageron A., et al. Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke. Stroke 2010, 41:1394-1404.
26. Friebe D., Neef M., Kratzsch J., et al. Leukocytes are a major source of circulating nicotinamide phosphoribosyltransferase (Nampt)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia 2011, epub.
27. Dahl T.B., Yndestad A., Skjelland M., et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007, 115:972-980.
28. Mayi T.H., Rigamonti E., Pattou F., Staels B., Chinetti-Gbaguidi G. Liver X Receptor (LXR) activation negatively regulates visfatin expression in macrophages. Biochem Biophys Res Commun 2011, 404:458-462.
29. Curat C.A., Wegner V., Sengenes C., et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006, 49:744-747.
30. Imai S. Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr Pharm Des 2009, 15:20-28.
31. Galli M., Van G.F., Rongvaux A., Andris F., Leo O. The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer. Cancer Res 2010, 70:8-11.
32. Liu S.W., Qiao S.B., Yuan J.S., Liu D.Q. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol Oxf 2009, 71:202-207.
33. Kadoglou N.P., Gkontopoulos A., Kapelouzou A., et al. Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study. Clin Chim Acta 2011, 412:48-52.
34. Kloting N., Graham T.E., Berndt J., et al. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab 2007, 6:79-87.
35. Broch M., Auguet M.T., Ramirez R., et al. Parallel downregulation of retinol-binding protein-4 and adiponectin expression in subcutaneous adipose tissue of non-morbidly obese subjects. Eur J Endocrinol 2009, 161:87-94.
36. von Eynatten M., Humpert P.M. Retinol-binding protein 4 & atherosclerosis: risk factor or innocent bystander?. Atherosclerosis 2009, 206:38-39.
37. Stuck B.J., Kahn B.B. Retinol-binding protein 4 (RBP4): a biomarker for subclinical atherosclerosis?. Am J Hypertens 2009, 22:948-949.
38. Park S.E., Kim D.H., Lee J.H., et al. Retinol-binding protein-4 is associated with endothelial dysfunction in adults with newly diagnosed type 2 diabetes mellitus. Atherosclerosis 2009, 204:23-25.
39. Ingelsson E., Sundstrom J., Melhus H., et al. Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly. Atherosclerosis 2009, 206:239-244.
40. Bobbert T., Raila J., Schwarz F., et al. Relation between retinol, retinol-binding protein 4, transthyretin and carotid intima media thickness. Atherosclerosis 2010, 213:549-551.
41. Cabre A., Lazaro I., Girona J., et al. Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes. J Intern Med 2007, 262:496-503.
42. Solini A., Santini E., Madec S., Rossi C., Muscelli E. Retinol-binding protein-4 in women with untreated essential hypertension. Am J Hypertens 2009, 22:1001-1006.
43. von Eynatten M., Humpert P.M. Retinol-binding protein-4 in experimental and clinical metabolic disease. Expert Rev Mol Diagn 2008, 8:289-299.
44. von Eynatten M., Lepper P.M., Liu D., et al. Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia 2007, 50:1930-1937.
45. Graham T.E., Yang Q., Bluher M., et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006, 354:2552-2563.
46. Quadro L., Hamberger L., Colantuoni V., Gottesman M.E., Blaner W.S. Understanding the physiological role of retinol-binding protein in vitamin A metabolism using transgenic and knockout mouse models. Mol Aspects Med 2003, 24:421-430.
47. Ng T.W., Watts G.F., Barrett P.H., Rye K.A., Chan D.C. Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care 2007, 30:2945-2950.
48. Coward P., Conn M., Tang J., et al. Application of an allosteric model to describe the interactions among retinol binding protein 4, transthyretin, and small molecule retinol binding protein 4 ligands. Anal Biochem 2009, 384:312-320.
49. Szabo A., Laki J., Madsen H.O., et al. Early rise in serum VEGF and PDGF levels predisposes patients with a normal MBL2 genotype to restenosis after eversion endarterectomy. Stroke 2007, 38:2247-2253.
50. Handa N., Matsumoto M., Maeda H., et al. Ultrasonic evaluation of early carotid atherosclerosis. Stroke 1990, 21:1567-1572.